Paper Details

  1. Home
  2. Paper Details

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

Author: CantrellL, CohoonA, DingK, DockeryL E, DuskaL R, EricksonB K, HolmanL L, JacksonC G, LandrumL M, MannelR S, MooreK N, MoxleyK M, QueimadoL, RichardsonD L, WalkerJ L

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the efficacy and tolerability of bevacizumab combined with rucaparib in patients with recurrent cervical or endometrial cancer. The combination did not demonstrate significant improvement in anti-tumor activity overall, but patients with ARID1A mutations showed a higher response rate and progression-free survival.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The aim of this study was to examine the tolerability and efficacy of combination bevacizumab rucaparib therapy in patients with recurrent cervical or endometrial cancer. PATIENTS & METHODS: Thirty-three patients with recurrent cervical or endometrial cancer were enrolled. Patients were ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/35491267

データ提供：米国国立医学図書館（NLM）

Investigating Bevacizumab and Rucaparib in Recurrent Cervical or Endometrial Cancer

Recurrent cervical or endometrial cancer is a challenging disease, and finding effective treatments is a priority. This research explores the potential of combining bevacizumab and rucaparib as a therapy for patients with recurrent cervical or endometrial cancer. Imagine a desert traveler facing a treacherous sandstorm. Similarly, cancer cells can be resilient, requiring a multi-pronged approach to combat their growth.

Combined Therapy Shows Limited Efficacy but Potential for a Subgroup

The study found that the combination of bevacizumab and rucaparib did not significantly improve the response rate or progression-free survival in all patients. However, there was a notable response in patients with ARID1A mutations. This is like finding a specific type of plant that thrives in a particular area of the desert, suggesting a potential for targeted therapies.

Further Research Needed to Investigate ARID1A Mutations

This research highlights the potential for personalized therapy for patients with recurrent cervical or endometrial cancer. Just as a camel navigates different terrains using different strategies, we need to find tailored approaches for treating cancer based on individual genetic profiles. The study underscores the need for further research to confirm the effectiveness of this combination therapy in patients with ARID1A mutations.

Dr.Camel's Conclusion

This study is a reminder that cancer treatment is a complex journey. Just as a camel needs to navigate various obstacles in the desert, researchers are constantly seeking new approaches to combat cancer. While this study found limited overall efficacy for the combination therapy, it provides a starting point for further research into personalized therapies tailored to specific genetic mutations. The pursuit of better cancer treatments continues, and the quest for targeted therapies holds great promise for the future.

Date :
  1. Date Completed 2022-06-22
  2. Date Revised 2023-08-17
Further Info :

Pubmed ID

35491267

DOI: Digital Object Identifier

NIHMS1873558

Related Literature

Article Analysis
・Effects of rucaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.